<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263038</url>
  </required_header>
  <id_info>
    <org_study_id>2019-02297</org_study_id>
    <nct_id>NCT04263038</nct_id>
  </id_info>
  <brief_title>Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism</brief_title>
  <acronym>SAFE-SSPE</acronym>
  <official_title>Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drahomir Aujesky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schweizerischer Nationalfonds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Ottawa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary
      arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial.
      Whether isolated SSPE represents &quot;true&quot; PE, a clinically more benign form of PE, a
      physiologic lung clearing process, or a false positive result (artifact) is currently unclear
      and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is
      uncertain. Despite growing evidence from observational studies that withholding
      anticoagulation may be a safe option in selected patients with isolated SSPE (i.e., those
      without concomitant deep vein thrombosis, cancer, etc.), most patients with isolated SSPE
      receive anticoagulant treatment, which is associated with an increased risk of bleeding. The
      overall objective of the randomized controlled SAFE-SSPE trial is to evaluate the efficacy
      and safety of clinical surveillance without anticoagulation compared to anticoagulation
      treatment in low-risk patients with isolated SSPE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent venous thromboembolism</measure>
    <time_frame>Within 90 days of randomization</time_frame>
    <description>Proportion of recurrent, clinically symptomatic, objectively confirmed venous thromboembolism (defined as recurrent fatal or nonfatal pulmonary embolism or lower limb deep vein thrombosis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically significant bleeding</measure>
    <time_frame>Within 90 days of randomization</time_frame>
    <description>Proportion of the composite of major and clinically relevant non-major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Within 90 days of randomization</time_frame>
    <description>Proportion of deaths (all causes of death will be considered)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Within 90 days of randomization</time_frame>
    <description>Pulmonary embolism related quality of life as assessed by the Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional status</measure>
    <time_frame>Within 90 days of randomization</time_frame>
    <description>Functional status as assessed by the post-venous thromboembolism functional status scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Initial length of stay (LOS)</measure>
    <time_frame>Within 90 days of randomization</time_frame>
    <description>Defined as the time/date of discharge minus time/date of admission at the emergency department</description>
  </other_outcome>
  <other_outcome>
    <measure>Subsequent overall hospitalizations</measure>
    <time_frame>Within 90 days of randomization</time_frame>
    <description>Number of overall hospitalizations</description>
  </other_outcome>
  <other_outcome>
    <measure>Emergency departments and physician outpatient visits</measure>
    <time_frame>Within 90 days of randomization</time_frame>
    <description>Number of emergency department and physician outpatient visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Return to work or usual activities</measure>
    <time_frame>Within 90 days of randomization</time_frame>
    <description>Time (days) to return to work in workers and usual activities (household) in non-workers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Embolism</condition>
  <condition>Embolism and Thrombosis</condition>
  <condition>Lung Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Anticoagulant-induced Bleeding</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the anticoagulation group will receive rivaroxaban 15 mg twice daily for the first 21 days, followed by 20 mg once daily for an overall treatment duration of 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No anticoagulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the group without anticoagulation will receive placebo twice daily for the first 21 days, followed by one tablet daily for an overall treatment duration of 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Anticoagulation</description>
    <arm_group_label>Anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study drug without active agent</description>
    <arm_group_label>No anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed Consent as documented by signature

          2. Age ≥18 years

          3. Objective diagnosis of symptomatic or asymptomatic isolated SSPE

        Exclusion Criteria:

          1. Presence of leg deep vein thrombosis (DVT) or upper extremity DVT (subclavian vein or
             above)

          2. Active cancer, defined as cancer treated with surgery, chemotherapy, radiotherapy, or
             palliative care during the last 6 months

          3. ≥1 prior episode of unprovoked VTE (absence of a transient or permanent risk factor)

          4. Clinical instability (systolic blood pressure &lt;100 mm Hg or arterial Oxygen saturation
             &lt;92% at ambient air) at the time of presentation

          5. Active bleeding or at high risk of bleeding

          6. Severe renal failure (creatinine clearance &lt;30ml/min)

          7. Severe liver insufficiency (Child-Pugh B or C)

          8. Concomitant use of strong CYP3A4 inhibitors or strong CYP3A4 inducers

          9. Known hypersensitivity to rivaroxaban

         10. Need for therapeutic anticoagulation for another reason

         11. Therapeutic anticoagulation for &gt;72 hours for any reason at the time of screening

         12. Hospitalized for &gt;72 hours prior to the diagnosis of isolated SSP (hospital-acquired
             VTE)

         13. Known pregnancy or breast feeding (pregnancy test to be performed for women of
             childbearing potential)

         14. Lack of safe contraception in women of childbearing potential

         15. Refusal or inability to provide informed consent

         16. Prior enrolment in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Drahomir Aujesky, Prof. MD MSc</last_name>
    <role>Study Director</role>
    <affiliation>Inselspital, Bern University Hospital, University of Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drahomir Aujesky, Prof. MD MSc</last_name>
    <phone>+41 31 632 88 84</phone>
    <email>SAFE-SSPE@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Baumgartner, Dr. MD MAS</last_name>
    <phone>+41 31 632 57 69</phone>
    <email>SAFE-SSPE@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Carrier, Prof. MD MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronne Mairuhu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HMC Westeinde</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Herman Hofstee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michiel Eijsvogel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tergooi ziekenhuis</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pieter W. Kamphuisen, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederikus A. Klok, Prof. MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne ziekenhuis</name>
      <address>
        <city>Leiderdorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antionio I. del Sol, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Universitair Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marieke Kruip, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of Aarau</name>
      <address>
        <city>Aarau</city>
        <state>Aargau</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Schütz, Prof. MD MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of Liestal</name>
      <address>
        <city>Liestal</city>
        <state>Basel</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Leuppi, Prof. MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Bienne</name>
      <address>
        <city>Bienne</city>
        <state>Bern</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Genné, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <state>Saint Gallen</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Sieber, MD MHA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of Olten</name>
      <address>
        <city>Olten</city>
        <state>Solothurn</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lukas Zimmerli, PD MD EMBA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <state>Thurgau</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Kistler, PD MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of Uri</name>
      <address>
        <city>Altdorf</city>
        <state>Uri</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Mang, KD MD MBA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Sion</name>
      <address>
        <city>Sion</city>
        <state>Valais</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Auguste Petignat, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Méan, MD MER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Nyon</name>
      <address>
        <city>Nyon</city>
        <state>Vaud</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Fumeaux, Prof MD EMBA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of Winterthur</name>
      <address>
        <city>Winterthur</city>
        <state>Zurich</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reinhard Imoberdorf, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of Baden</name>
      <address>
        <city>Baden</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürg-Hans Beer, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Bingisser, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drahomir Aujesky, Prof. MD MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tiefenau Hospital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Essig, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Hospital of Emmental</name>
      <address>
        <city>Burgdorf</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Escher, PD Dr. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Delémont</name>
      <address>
        <city>Delémont</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé Duplain, PD Dr. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of Fribourg</name>
      <address>
        <city>Fribourg</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Hayoz, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geneva University Hospital</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Righini, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of Lucerne</name>
      <address>
        <city>Lucerne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Henzen, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Neuchâtel</name>
      <address>
        <city>Neuchâtel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Donzé, Prof. MD MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triemli Hospital</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Huber, PD MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Keller-Lang, Prof. MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Inselspital, Berne</investigator_affiliation>
    <investigator_full_name>Drahomir Aujesky</investigator_full_name>
    <investigator_title>Prof. Dr., MD, MSc</investigator_title>
  </responsible_party>
  <keyword>subsegmental pulmonary embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Embolism and Thrombosis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publication of the study results, a de-identified patient-level data set relating to the primary publication along with the latest version of the study protocol, the informed consent form, the statistical analysis plan, the code used for the analyses, and the Data Management and Quality Plan describing all data management aspects of the study will be made publicly available for replication of the study results and secondary data analyses in the Bern Open Repository and Information System (BORIS) Research Data, an online non-commercial data repository that meets Swiss National Science Foundation requirements for FAIR Data Principles (www.force11.org/group/fairgroup/fairprinciples)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After publication of the study results</ipd_time_frame>
    <ipd_access_criteria>Data will be publicly available for replication of the study results and secondary data analyses in the Bern Open Repository and Information System (BORIS) Research Data</ipd_access_criteria>
    <ipd_url>https://www.boris.unibe.ch/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

